4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Ependymoma by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 153 ongoing clinical trials involving Ependymoma
Of the 153 trials,49 trials are in Phase II
Furthermore, 39 trials are in Phase I/II

Number of ongoing Clinical Trials (for drugs) involving Ependymoma by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Ependymoma, an oncology condition. The largest number of ongoing clinical trials for Ependymoma is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Ependymoma-related drug trials.

National Cancer Institute US: The leading ongoing Ependymoma related clinical trial sponsor

National Cancer Institute US is the top sponsor for Ependymoma-related ongoing clinical trials.

Children's Oncology Group, Seattle Children's Hospital, University of Texas Health Science Center at Houston, St. Jude Children’s Research Hospital Inc, and Bristol-Myers Squibb Co are among other notable clinical trial sponsors involved in Ependymoma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Ependymoma

Carmustine and Teniposide (Vumon) are key marketed drugs involving Ependymoma.

Carmustine acts as an alkylating agent. It functions via DNA Synthesis inhibitors mechanism of action. It is formulated as a lyophilized powder for solution intravenous route of administration. Carmustine is used as palliative therapy for brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors as a single agent, and for multiple myeloma in combination with prednisone. Carmustine was first approved in 2021 and is marketed in the US by Meitheal Pharmaceuticals Inc.

Teniposide (Vumon) is a semisynthetic podophyllotoxin derivative, acts as an anti-neoplastic agent. It functions via DNA Topoisomerase II (EC 5.99.1.3) Inhibitor mechanism of action. It is formulated as an injectable solution for the intravenous route of administration. Vumon is indicated for the treatment of refractory childhood acute lymphoblastic leukemia, acute lymphoblastic leukemia, hodgkins and non-hodgkin lymphoma, generalized malignant lymphoma (stages 3 and 4), reticulum cell sarcoma, lymphatic sarcoma, brain (brain tumor), kyoya cell tumors, astrocytoma, glioblastoma, and neuroblastoma. Teniposide was first approved in 1982 and is marketed globally including the US, Australia, Spain, and China by HQ Speciality Pharma.